It makes my head spin to think about how much GLP-1s have changed the medical weight management landscape in such a short time.
In 2023, I wrote for STAT about GLP-1 shortages leading to treatment delays, interruptions, and difficult decisions about who “deserved” to get these precious medications. I struggled in particular with the ethical dilemma of robbing Peter to pay Paul: prescribing GLP-1s that are specifically approved for type 2 diabetes to people without diabetes for weight loss.
